Comparative efficacy data are not necessarily required for approval but are increasingly demanded by payers. Meeting the expectations of all stakeholders can be challenging, making comparator selection and trial design complex decisions.
High Phase II attrition is hampering the pharma industry’s ability to reach sustainable rates of innovation. More rigorous validation of new biological targets prior to clinical development is essential for increasing R&D efficiency.
This report reviews the different types of relationship models between contract research organizations (CROs) and sponsors, and forecasts the leading next-wave clinical trial destinations.
Edit my basket
© Datamonitor 2014. All rights reserved
Terms & Conditions